Suppr超能文献

新型氟喹诺酮类药物DU-6859a的体外抗菌活性

In vitro antibacterial activity of DU-6859a, a new fluoroquinolone.

作者信息

Nakane T, Iyobe S, Sato K, Mitsuhashi S

机构信息

Episome Institute, Gunma, Japan.

出版信息

Antimicrob Agents Chemother. 1995 Dec;39(12):2822-6. doi: 10.1128/AAC.39.12.2822.

Abstract

The in vitro antibacterial activity of DU-6859a, a new fluoroquinolone, against a wide variety of clinical isolates was evaluated and compared with those of tosufloxacin, ofloxacin, ciprofloxacin, and sparfloxacin. DU-6859a showed potent broad-spectrum activity against gram-positive, gram-negative, and anaerobic bacteria, and its activity was greater than those of the control quinolones. By comparison of MICs at which 90% of strains are inhibited, DU-6859a had potent activity against bacteria resistant to the control quinolones. The time-killing curves of quinolones showed that the number of viable cells decreased rapidly during 2 to 4 of incubation, and regrowth was not seen even after 8 h incubation. At a concentration of four times the MIC, the frequencies of appearance of spontaneous mutants of Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa resistant to DU-6859a were < or = 4.0 x 10(-9) to 1.9 x 10(-8). The 50% inhibitory concentrations of DU-6859a were 0.86 and 1.05 micrograms/ml for the supercoiling activities of DNA gyrases isolated from E. coli and P. aeruginosa, respectively. The rank order of the 50% inhibitory concentrations observed for both DNA gyrases roughly paralleled the MICs.

摘要

对新型氟喹诺酮类药物DU-6859a针对多种临床分离菌株的体外抗菌活性进行了评估,并与托氟沙星、氧氟沙星、环丙沙星和司帕沙星进行了比较。DU-6859a对革兰氏阳性菌、革兰氏阴性菌和厌氧菌显示出强大的广谱活性,且其活性大于对照喹诺酮类药物。通过比较抑制90%菌株生长的最低抑菌浓度(MIC),DU-6859a对耐对照喹诺酮类药物的细菌具有强大活性。喹诺酮类药物的杀菌曲线表明,在培养2至4小时期间活细胞数量迅速减少,甚至在培养8小时后也未见再生长。在四倍MIC浓度下,金黄色葡萄球菌、大肠杆菌和铜绿假单胞菌对DU-6859a耐药的自发突变体出现频率≤4.0×10⁻⁹至1.9×10⁻⁸。DU-6859a对从大肠杆菌和铜绿假单胞菌中分离的DNA回旋酶超螺旋活性的50%抑制浓度分别为0.86和1.05微克/毫升。观察到的两种DNA回旋酶的50%抑制浓度的排序大致与MICs平行。

相似文献

1
In vitro antibacterial activity of DU-6859a, a new fluoroquinolone.
Antimicrob Agents Chemother. 1995 Dec;39(12):2822-6. doi: 10.1128/AAC.39.12.2822.
4
Bactericidal activities of DU-6859a and clinafloxacin (CI-960) against staphylococci.
Antimicrob Agents Chemother. 1994 Aug;38(8):1868-70. doi: 10.1128/AAC.38.8.1868.
5
In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone.
Antimicrob Agents Chemother. 1994 Mar;38(3):594-601. doi: 10.1128/AAC.38.3.594.
6
In vitro activity of DU-6859a against anaerobic bacteria.
Antimicrob Agents Chemother. 1994 Oct;38(10):2504-9. doi: 10.1128/AAC.38.10.2504.
7
Bactericidal activity of the new 4-quinolones DU-6859a and DV-7751a.
J Med Microbiol. 1995 Jul;43(1):4-8. doi: 10.1099/00222615-43-1-4.
8
The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones.
J Antimicrob Chemother. 1998 Aug;42(2):179-87. doi: 10.1093/jac/42.2.179.
10
In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a.
Antimicrob Agents Chemother. 1994 Dec;38(12):2877-82. doi: 10.1128/AAC.38.12.2877.

引用本文的文献

1
Antipneumococcal activity of DK-507k, a new quinolone, compared with the activities of 10 other agents.
Antimicrob Agents Chemother. 2003 Dec;47(12):3815-24. doi: 10.1128/AAC.47.12.3815-3824.2003.
2
In vitro and in vivo activities of sitafloxacin against Chlamydia spp.
Antimicrob Agents Chemother. 2001 Nov;45(11):3270-2. doi: 10.1128/AAC.45.11.3270-3272.2001.
3
In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates.
Antimicrob Agents Chemother. 2000 Apr;44(4):1102-7. doi: 10.1128/AAC.44.4.1102-1107.2000.
4
Pharmacokinetics and pharmacodynamics of fluoroquinolones.
Drugs. 1999;58 Suppl 2:29-36. doi: 10.2165/00003495-199958002-00006.
5
Activity of newer fluoroquinolones in vitro against gram-positive bacteria.
Drugs. 1999;58 Suppl 2:23-8. doi: 10.2165/00003495-199958002-00005.
6
Ofloxacin otic solution: a review of its use in the management of ear infections.
Drugs. 1999 Sep;58(3):509-31. doi: 10.2165/00003495-199958030-00019.
7
Cloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IV.
Antimicrob Agents Chemother. 1999 Mar;43(3):530-6. doi: 10.1128/AAC.43.3.530.

本文引用的文献

1
In vitro and in vivo activity of DL-8280, a new oxazine derivative.
Antimicrob Agents Chemother. 1982 Oct;22(4):548-53. doi: 10.1128/AAC.22.4.548.
2
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.
Antimicrob Agents Chemother. 1983 Apr;23(4):559-64. doi: 10.1128/AAC.23.4.559.
3
Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies.
J Bacteriol. 1969 Jul;99(1):238-41. doi: 10.1128/jb.99.1.238-241.1969.
5
Purification and properties of DNA gyrase from a fluoroquinolone-resistant strain of Escherichia coli.
Antimicrob Agents Chemother. 1986 Nov;30(5):777-80. doi: 10.1128/AAC.30.5.777.
6
In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone.
Antimicrob Agents Chemother. 1988 Jun;32(6):827-33. doi: 10.1128/AAC.32.6.827.
7
In vitro activity of AT-4140 against clinical bacterial isolates.
Antimicrob Agents Chemother. 1989 Nov;33(11):1980-8. doi: 10.1128/AAC.33.11.1980.
8
Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates.
Antimicrob Agents Chemother. 1992 Jul;36(7):1491-8. doi: 10.1128/AAC.36.7.1491.
9
DNA gyrase: an enzyme that introduces superhelical turns into DNA.
Proc Natl Acad Sci U S A. 1976 Nov;73(11):3872-6. doi: 10.1073/pnas.73.11.3872.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验